These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 33868727)

  • 1. Tuberculosis Drug Susceptibility, Treatment, and Outcomes for Belarusian HIV-Positive Patients with Tuberculosis: Results from a National and International Laboratory.
    Podlekareva DN; Folkvardsen DB; Skrahina A; Vassilenko A; Skrahin A; Hurevich H; Klimuk D; Karpov I; Lundgren JD; Kirk O; Lillebaek T
    Tuberc Res Treat; 2021; 2021():6646239. PubMed ID: 33868727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal trend of drug-resistant tuberculosis among Thai children during 2006-2021.
    Jantarabenjakul W; Supradish Na Ayudhya P; Suntarattiwong P; Thepnarong N; Rotcheewaphan S; Udomsantisuk N; Moonwong J; Kosulvit P; Tawan M; Sudjaritruk T; Puthanakit T
    IJID Reg; 2022 Dec; 5():79-85. PubMed ID: 36238580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Principles of chemotherapy for tuberculosis in national tuberculosis programmes of low- and middle-income countries.
    Chiang CY; Lin CJ
    Indian J Tuberc; 2020 Dec; 67(4S):S16-S22. PubMed ID: 33308663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of microscopic observation drug susceptibility testing for rapid, direct rifampicin and isoniazid drug susceptibility testing in patients receiving tuberculosis treatment.
    Coronel J; Roper MH; Herrera C; Bonilla C; Jave O; Gianella C; Sabogal I; Huancaré V; Leo E; Tyas A; Mendoza-Ticona A; Caviedes L; Moore DA
    Clin Microbiol Infect; 2014 Jun; 20(6):536-41. PubMed ID: 24107197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment outcomes for isoniazid-monoresistant tuberculosis in Peru, 2012-2014.
    Cornejo Garcia JG; Alarcón Guizado VA; Mendoza Ticona A; Alarcon E; Heldal E; Moore DAJ
    PLoS One; 2018; 13(12):e0206658. PubMed ID: 30513085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparisons of whole-genome sequencing and phenotypic drug susceptibility testing for Mycobacterium tuberculosis causing MDR-TB and XDR-TB in Thailand.
    Faksri K; Kaewprasert O; Ong RT; Suriyaphol P; Prammananan T; Teo YY; Srilohasin P; Chaiprasert A
    Int J Antimicrob Agents; 2019 Aug; 54(2):109-116. PubMed ID: 30981926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The management of tuberculosis: epidemiology, resistance and monitoring.
    Bang D
    Dan Med Bull; 2010 Nov; 57(11):B4213. PubMed ID: 21055374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of line probe assay to BACTEC MGIT 960 system for susceptibility testing of first and second-line anti-tuberculosis drugs in a referral laboratory in South Africa.
    Maningi NE; Malinga LA; Antiabong JF; Lekalakala RM; Mbelle NM
    BMC Infect Dis; 2017 Dec; 17(1):795. PubMed ID: 29282012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
    Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
    Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of pre-extensively drug-resistant tuberculosis (Pre XDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) among extra pulmonary (EP) multidrug resistant tuberculosis (MDR-TB) at a tertiary care center in Mumbai in pre Bedaquiline (BDQ) era.
    Utpat KV; Rajpurohit R; Desai U
    Lung India; 2023; 40(1):19-23. PubMed ID: 36695254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethambutol-resistance testing by mutation detection using MTBDRsl.
    Margaryan H; Rüsch-Gerdes S; Hayrapetyan A; Mirzoyan A
    Int J Mycobacteriol; 2016 Dec; 5 Suppl 1():S50. PubMed ID: 28043606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discordance across Phenotypic and Molecular Methods for Drug Susceptibility Testing of Drug-Resistant Mycobacterium tuberculosis Isolates in a Low TB Incidence Country.
    Ahmad S; Mokaddas E; Al-Mutairi N; Eldeen HS; Mohammadi S
    PLoS One; 2016; 11(4):e0153563. PubMed ID: 27096759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tuberculosis Laboratory Surveillance Network (TuLSA) study group. The first step for national tuberculosis laboratory surveillance: Ankara, 2011].
    Sezen F; Albayrak N; Özkara Ş; Karagöz A; Alp A; Duyar Ağca F; İnan Süer A; Müderris T; Ceyhan İ; Durmaz R; Ertek M;
    Mikrobiyol Bul; 2015 Apr; 49(2):143-55. PubMed ID: 26167815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changing prevalence and resistance patterns in children with drug-resistant tuberculosis in Mumbai.
    Shah I; Shah F
    Paediatr Int Child Health; 2017 May; 37(2):135-138. PubMed ID: 27686119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-Genome Sequencing of Mycobacterium tuberculosis Provides Insight into the Evolution and Genetic Composition of Drug-Resistant Tuberculosis in Belarus.
    Wollenberg KR; Desjardins CA; Zalutskaya A; Slodovnikova V; Oler AJ; Quiñones M; Abeel T; Chapman SB; Tartakovsky M; Gabrielian A; Hoffner S; Skrahin A; Birren BW; Rosenthal A; Skrahina A; Earl AM
    J Clin Microbiol; 2017 Feb; 55(2):457-469. PubMed ID: 27903602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis.
    Al-Mutairi NM; Ahmad S; Mokaddas E; Eldeen HS; Joseph S
    BMC Infect Dis; 2019 Jan; 19(1):3. PubMed ID: 30606116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The diagnostic accuracy of the GenoType(®) MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs.
    Theron G; Peter J; Richardson M; Barnard M; Donegan S; Warren R; Steingart KR; Dheda K
    Cochrane Database Syst Rev; 2014 Oct; (10):CD010705. PubMed ID: 25353401
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.